Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022.
Title: LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.
About Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer.
The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens.
Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies.
LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens.
This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a U.S. based, healthcare-focused investment firm.
About LTX-315
LTX-315 is a potential first-in-class oncolytic molecule administered directly into a tumor to induce immunogenic cell death.
The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens.
LTX-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.
About in situ vaccination
